(Q34025763)

English

The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

Sabine Riethdorf

6

object named as

Sabine Riethdorf

0 references

11

object named as

Klaus Pantel

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

author name string

Jayaprakash Karkera

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Hannes Steiner

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Weimin Li

3

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Viktor Skradski

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Patrizia L Moser

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Manjula Reddy

7

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Thomas Puchalski

8

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Karim Safer

9

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Uma Prabhakar

10

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Ming Qi

12

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Zoran Culig

13

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

publication date

14 February 2011

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

71

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1455-1465

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Interleukin-6: a candidate mediator of human prostate cancer morbidity

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21362

21 January 2018

Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21362

21 January 2018

Interleukin-6 regulation of prostate cancer cell growth

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21362

21 January 2018

Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21362

21 January 2018

An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21362

21 January 2018

Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21362

21 January 2018

Interleukin-6 inhibits the growth of prostate cancer xenografts in mice by the process of neuroendocrine differentiation

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21362

21 January 2018

Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21362

21 January 2018

Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21362

21 January 2018

CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21362

21 January 2018

Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21362

21 January 2018

Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21362

21 January 2018

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21362

21 January 2018

Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21362

21 January 2018

Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21362

21 January 2018

Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21362

21 January 2018

STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21362

21 January 2018

Stat3 promotes metastatic progression of prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21362

21 January 2018

Vitamin D may reduce prostate cancer metastasis by several mechanisms including blocking Stat3.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21362

21 January 2018

Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21362

21 January 2018

A novel role of Shc adaptor proteins in steroid hormone-regulated cancers.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21362

21 January 2018

Gene expression analysis of prostate cancers

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21362

21 January 2018

Gene expression profiling identifies clinically relevant subtypes of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21362

21 January 2018

Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21362

21 January 2018

Tumor immunobiological differences in prostate cancer between African-American and European-American men.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21362

21 January 2018

Androgen increases androgen receptor protein while decreasing receptor mRNA in LNCaP cells

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21362

21 January 2018

17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21362

21 January 2018

Interleukin-6 regulates androgen synthesis in prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21362

21 January 2018

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21362

21 January 2018

Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21362

21 January 2018

Grb2 signaling in cell motility and cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21362

21 January 2018

Identifiers

10.1002/PROS.21362

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34025763&oldid=1763415626"